Sanofi, Regeneron Begin Kevzara Clinical Trial For Severe COVID-19 - Quick Facts

Sanofi (SNY, SNYNF) and Regeneron Pharmaceuticals, Inc. (REGN) announced Monday they have started a clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe coronavirus (COVID-19).

from RTT - Biotech https://ift.tt/2x1IoxM
via IFTTT